Some soreness can wait, and some should not

Mild soreness can have a short trial of home care

If the joint aches after extra work but eases with rest, try gentle movement and shorter periods of activity. Heat can loosen stiffness. Cold may calm swelling. Unless your doctor told you otherwise, keep getting up and moving during the day.

Basic care means regular exercise suited to the joint, pacing hard chores, and using a brace or cane when advised. Medicine may help if your doctor says it is safe. A fair trial means following that plan long enough for your doctor or physical therapist to judge it, not trying it once.

If soreness keeps taking more from your day, arrange an exam.

Heat, fever, or sudden weakness needs quicker care

Get urgent medical care when fever comes with a joint that feels hot and looks swollen. A changed joint shape or sudden trouble bearing weight after an injury also needs prompt care. New numbness or weakness with back pain shouldn't wait. A swollen, red, or painful calf after a procedure needs quick help too.

Call a doctor about soreness that stays worse at rest, unexplained weight loss, or new bone pain if you've had cancer. After any joint procedure, seek help for fever, redness that spreads, or pain that keeps rising.

Those signs need medical care, not a routine clinic talk.

The exam decides which care makes sense

For soreness without warning signs, QC Kinetix offers a consultation about regenerative treatments. They're non-surgical procedures done in the clinic. Medical providers will examine you, provide the care, and explain whether it fits. One procedure may draw your blood, spin it, and put the concentrated blood into the sore joint.

Bring an earlier X-ray and a list of every medicine you take. Explain which tasks are hard and which movements worsen the soreness. The provider may say home care needs more time. If the exam and X-ray show severe wear, surgery may deserve the fuller discussion.

Not every aching joint needs a clinic procedure.

Sources

1. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. A systematic review of 21 studies re-examining the familiar '20 percent are dissatisfied after knee replacement' figure found the actual average dissatisfaction rate was 10 percent, and 7.3 percent when complications were excluded - the surgical benchmark a cash-pay injection is implicitly competing against.

   DeFrance MJ, et al. — Are 20% of Patients Actually Dissatisfied Following Total Knee Arthroplasty? A Systematic Review of the Literature. J Arthroplasty, 2023. DOI: 10.1016/j.arth.2022.10.011.

3. The AAOS Surgical Management of Osteoarthritis of the Knee clinical practice guideline sets out 16 recommendations and seven options for surgical management based on a systematic review of the published evidence - the reference point for when a joint has moved past the injectable tier.

   Srivastava AK, et al. — American Academy of Orthopaedic Surgeons Clinical Practice Guideline Summary of Surgical Management of Osteoarthritis of the Knee. J Am Acad Orthop Surg, 2023. DOI: 10.5435/JAAOS-D-23-00338.

4. A 2025 randomized trial of 66 knee osteoarthritis patients compared a single adipose stromal vascular fraction injection, conventional rehabilitation alone, and the two combined over 12 months - a design that treats exercise-based rehabilitation as a genuine comparator rather than an afterthought.

   Lu J, et al. — Intraarticular injection of the stromal vascular fraction for the treatment of knee osteoarthritis a prospective randomized controlled clinical trial. Sci Rep, 2025. DOI: 10.1038/s41598-025-09398-w.

5. MACI is FDA-licensed (STN BL 125603, Vericel Corporation) and is indicated for the repair of symptomatic, single or multiple FULL-THICKNESS cartilage defects of the knee with or without bone involvement in adults - a focal defect repair performed surgically, not a treatment for osteoarthritis and not an injection.

   US Food and Drug Administration — MACI (autologous cultured chondrocytes on porcine collagen membrane). , 2016.

6. In orders issued 26 December 2024 and announced 8 January 2025, a federal court permanently banned the co-founders of the Stem Cell Institute of America and their companies from marketing any regenerative medicine treatment, and ordered $5,155,146 in refunds and civil penalties. The court found on summary judgment that they published false and misleading advertisements about the efficacy and approval of stem cell injections for osteoarthritis, neuropathy and joint pain; their clinic charged up to $5,000 per injection and the customers were almost exclusively elderly and disabled people.

   US Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. , 2025.

7. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.